Efficacy and safety of omalizumab in paediatric age: an update of literature data.

Document Type

Article

Abstract

Immunoglobulin E (IgE) was discovered in 1966 and was found responsible for immune defense against helminths, type I hypersensitivity and allergic diseases. IgE mediates allergic responses by binding to Fc receptors (the high affinity Fc-epsilon receptor I and the low affinity Fc-epsilon receptor II or CD23) expressed on tissue mast cells and blood basophils. This binding leads to degranulation and release of pro-inflammatory mediators. Considering the pivotal role of IgE in allergic diseases, antibodies against IgE potentiate an array of new therapeutic strategies and in this regard omalizumab (rhuMAb-E25, Xolair) has been developed as a monoclonal biologic drug to block serum IgEs. Although the use of omalizumab has been studied vigorously in many adult populations with allergic diseases, there are few heterogenous studies on children. There are very few ongoing clinical trials with omalizumab exclusively on children, although some adult studies have concluded pediatric patients as a part of their studies. Nevertheless, in pediatric clinical trials omalizumab has been demonstrated to be effective and safe also in this age group. Herein, the authors present a systematic review of extensive literature data on the use of omalizumab in children and adolescents.

Medical Subject Headings

Anti-Allergic Agents; Asthma; Child; Clinical Trials as Topic; Dermatitis, Atopic; Food Hypersensitivity; Humans; Omalizumab; Urticaria

Publication Date

1-1-2016

Publication Title

Journal of biological regulators and homeostatic agents

ISSN

0393-974X

Volume

30

Issue

2

First Page

579

Last Page

584

PubMed ID

27358151

This document is currently not available here.

Share

COinS